A detailed history of Park Place Capital Corp transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Park Place Capital Corp holds 370 shares of VRTX stock, worth $175,590. This represents 0.06% of its overall portfolio holdings.

Number of Shares
370
Previous 792 53.28%
Holding current value
$175,590
Previous $331,000 47.73%
% of portfolio
0.06%
Previous 0.12%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 02, 2024

SELL
$392.81 - $485.53 $165,765 - $204,893
-422 Reduced 53.28%
370 $173,000
Q1 2024

Apr 18, 2024

SELL
$407.69 - $446.08 $206,698 - $226,162
-507 Reduced 39.03%
792 $331,000
Q4 2023

Jan 24, 2024

BUY
$343.0 - $410.68 $98,098 - $117,454
286 Added 28.23%
1,299 $528,000
Q3 2023

Oct 17, 2023

SELL
$338.18 - $362.46 $70,003 - $75,029
-207 Reduced 16.97%
1,013 $352,000
Q2 2023

Aug 04, 2023

SELL
$314.42 - $351.91 $66,971 - $74,956
-213 Reduced 14.86%
1,220 $429,000
Q1 2023

May 02, 2023

SELL
$283.23 - $323.1 $188,631 - $215,184
-666 Reduced 31.73%
1,433 $451,000
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $599,810 - $674,786
2,099 New
2,099 $606,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Park Place Capital Corp Portfolio

Follow Park Place Capital Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Park Place Capital Corp, based on Form 13F filings with the SEC.

News

Stay updated on Park Place Capital Corp with notifications on news.